whoslets

The Unripe York Times on Friday examined how at least part of the new Medicare medicament panacea benefit might not necessarily be working as “Congress intended,” as some employers who provide retiree direction drug coverage are saying that retirees who choose to enroll in the new Medicare drug improve will lose all owner-sponsored fettle benefits. For the purpose instance, Boeing, in a correspondence literature recently sent to 100,000 retirees and their dependents, said, “[Y]our Boeing medicine dose coverage is more generous than standard Medicare remedy opiate coverage.” How in the world, the letter adds, “Your Boeing remedy drug coverage is shard of your Boeing retiree medical scenario. If you cancel your Boeing preparation drug coverage” to enroll in the fashionable Medicare drug allowances, “your Boeing medical coverage also will be canceled.” According to the Times, other companies — such as GM, Caterpillar, Verizon Communications, SBC Communications and the Southern Company — are informing retirees that their company medicament benefits are as saintly as or superior to the Medicare yardstick drug promote. In many cases, “plan sponsors are saying, ‘If you join Medicare Put asunder give up D, you will be out of our plot,’” Edward Kaplan, a senior haleness control counselor at the Segal Company, said. GM is a “notable exception” in that it is allowing retirees to memorize their health benefits even if they enroll in the new Medicare drug emoluments, the Times reports.

Explanation
According to the Times, the companies’ decision to drop all health benefits for retirees who enroll in the Medicare drug benefit might “be understandable.” Many employers provide drug benefits within a comprehensive medical benefits package and generally do not charge a separate premium for drug coverage. Some employers say it would be difficult to separate the drug coverage from the larger benefits packages they currently offer. In addition, companies have an incentive to continue to provide retiree drug coverage because they will receive a subsidy from CMS for each retiree enrolled in their drug plan. Companies “have shown little interest” in continuing to provide other, “increasingly expensive” medical benefits to retirees if it means they will lose the subsidies, the Times reports. The subsidies will equal 28% of a retiree’s drug costs, from $250 to $5,000 in 2006. The average subsidy will be about $668 per qualified retiree in 2006 with a maximum of $1,330 per retiree, according to the Bush administration. However, with the subsidy program expected to cost $71 million between 2006 and 2013, some analysts say it could face elimination under congressional cost-cutting efforts. Moreover, the subsidy, “[e]ven at the current level, … is not enough to offset employers’ rising health costs,” though companies such as Dow Chemical and IBM are using it partly to offset monthly premium increases for retiree health benefits (Freudenheim/Pear, New York Times, 11/4).

Electronic Prescribing
In related news, CMS has announced new rules for electronic prescribing standards under the Medicare drug benefit, CQ HealthBeat reports. In a news release, CMS Administrator Mark McClellan said, “We are making e-prescribing easier to implement, to accelerate the use of e-prescribing in Medicare and throughout the nation’s health care system.” He said all Medicare prescription drug plans must comply with the new standards by Jan. 1, 2006, when the new benefit begins (CQ HealthBeat, 11/3).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Two University of Virginia School of Nostrum researchers have been awarded grants from the National Establish of Allergy and Infectious Diseases to develop treatments and tests in return some rapidly emerging trouble spots in the area of gastrointestinal diseases.

Under these cooperative agreement (U01) grants, one scientist plans to develop a single test to tag more than 20 different food and waterborne pathogens while the minute at one’s desire create a single treatment which could protect people from comely infected with more than 20 potential pathogens.

These pathogens have ripen into splendidly known to the ordinary buyers in recent years, most importantly from cases of E. coli bacteria infecting the food supply. In 2006, three people died and hundreds more were sickened after eating E. coli contaminated spinach. Possibly the best known modern circumstance of large-scale public infection occurred in Milwaukee, Wisconsin in 1993. That year, more than 400,000 residents were sickened by Cryptosporidium parvum, a leech which infiltrated the city’s water cache. More than 100 people died as a rule result of being infected with the parasite.

“Detecting an outbreak of E. coli in the nourishment supply or cryptosporidium in the water give as lickety-split as attainable is vital if we are accepted to certify the safety of what we eat and drink,” says Dr. Eric Houpt, associate professor of medicine at the University of Virginia Devotees of Panacea. “The take exception to is developing a particular test for the treatment of the most common pathogens as opposed to just one test as regards one pathogen.”

Houpt will lead the team of researchers in developing the test, which includes scientists from Michigan Stately University, the Commonwealth of Virginia Division of Consolidated Laboratory Services, Kilimanjaro Christian Medical Center in Tanzania and the clandestinely sector. The resulting diagnostic exam could then be deployed to medical settings such as hospitals, clinics, or field sites.
Dr. Paul Hoffman, professor of medicine at the University of Virginia, is using his $2.6 million grant to develop another generation antiparasitic/antibacterial therapeutics to manipulation of infections caused by Giardia, Cryptosporidium, Campylobacter, Entamoeba and Clostridium difficile.

“These are all extremely nasty parasites to pick up and for divers people, especially people with weaker exempt systems, they can prove fatal because of the debilitating diarrhea associated with infection,” Hoffman says.

Working with pharmaceutical companies and University of Virginia professor of chemistry Timothy Macdonald, Hoffman’s group plans to use a novel drug target simple in parasites and undoubted bacteria by chemically modifying available drugs to improve their efficacy and distend the conditions they can treat.

“If we can put this medication in a unwed pill, we can prevent people from becoming ill from these parasites before they are exposed and treat them if they have been infected,” Hoffman says. “This could be used in preparation for a natural cataclysm where we know there will be parasitic outbreaks or in reply to a bioterrorism event.”

Houpt and Hoffman are optimistic the test and the treatment could be likely for testing within three years.

—————————-
Article adapted by Medical News Today from original newswomen put out.
—————————-

Commencement: David Foreman

University of Virginia Robustness Plan

A groundbreaking study led by Northwestern University researchers has demonstrated that a protein called alphaB-crystallin, which normally protects cells from stress damage, triggers events that may belief chest cancer when overactive.

Breast cancer is the most common cancer in women and is responsible for over 400,000 deaths annually in women throughout the world. Most of these deaths are the result of aggressive breast tumors that often fail to respond to current treatments.

The researchers found that women whose breast tumors express the alphaB-crystallin protein have a shorter survival, suggesting that alphaB-crystallin may be a useful molecular marker to identify women with aggressive breast cancer and to develop new targeted cancer therapies.

The study, which was published in the January issue of the Journal of Clinical Investigation, was led by Vincent L. Cryns, M.D., associate professor of medicine and director of the Cell Death Regulation Laboratory at Northwestern University Feinberg School of Medicine, and a researcher at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Cryns and colleagues found that introducing the alphaB-crystallin gene into non-cancerous breast cells transformed them into breast cancer cells. These experiments took advantage of a powerful technique to grow breast cells as three-dimensional (3D) gland-like structures that are similar to those present in the normal breast. However, when the researchers introduced alphaB-crystallin into non-cancerous breast cells, the cells started growing uncontrollably and formed enlarged 3D masses that resemble breast tumors.

The experiments were conducted by Jose V. Moyano, a post-doctoral fellow in the Cryns lab, who was lead author on the study.

“Basically, breast cancer cells have hijacked alphaB-crystallin, a protein that normally protects cells against stress injury and death, and used it to promote their uncontrolled growth,” Cryns reflected.

The investigators also showed that alphaB-crystallin activates a key molecular pathway, the MEK-ERK pathway, that leads to unrestrained cell growth in cancer, and that drug inhibitors of this pathway block the cancerous effects of alphaB-crystallin.

“Currently, we don’t have any targeted treatments like tamoxifen or Herceptin for the aggressive type of breast tumors that express alphaB-crystallin. Our results suggest that these tumors may respond to drugs that block this important pathway activated by alphaB-crystallin,” Cryns said.

Cryns’ laboratory group also observed that non-cancerous breast cells genetically manipulated to express alphaB-crystallin form aggressive breast tumors when injected into mice, confirming their malignant nature.

What’s more, the team found that these mouse tumors were similar in many respects to human breast tumors which express alphaB-crystallin, suggesting that this mouse model may be useful for testing new treatments for these poor-prognosis tumors. Indeed, the researchers are currently exploring whether drug inhibitors of the MEK-ERK pathway block breast tumor growth in mice.

Collaborating with Cryns and Moyano were Torsten O. Nielson and Dmitry Turbin, University of British Columbia, Vancouver; and Charles M. Perou and Gamze Karaca, University of North Carolina at Chapel Hill. Other members of the research team at Northwestern University were Fruma Yehiely, Joseph R. Evans, Feng Chen, Meiling Lu, Michael E. Werner, Leslie Diaz and Elizabeth Wiley.

http://www.northwestern.edu/

Use of the widely used birth control
pill, ORTHO TRI-CYCLEN(R) LO (norgestimate/ethinyl estradiol) Tablets,
resulted in significantly degrade rates of breakthrough bleeding and spotting
in a indefinite variety of women compared to another low-dose combination nativity
control pill, according to data presented today at the 55th Annual Clinical
Congregation of The American College of Obstetricians and Gynecologists
(ACOG).(1)

This inquiry compared the breakthrough bleeding and spotting profiles
of two low-dispense origination control pills, containing either 25 mcg or 20 mcg of
ethinyl estradiol and differing progestins, in women across a range of ages
and weights.

Breakthrough bleeding and spotting, which refers to strange or
unexpected bleeding between periods, is a side effect associated with the
use of birth control pills, especially low-dose pills, and is the cardinal
cause of dissatisfaction and discontinuation of oral contraceptive use. It
most commonly occurs in the start with few months of taking a unknown pill, and
commonly ceases at a go the portion adjusts to the hormonal dosage.

“Breakthrough bleeding is a bothersome side effect of using the Pill,”
said lead investigator Raymond Moss Hampton, M.D., Texas Tech University
Manner of Remedy. “These observations demonstrate that women using ORTHO
TRI-CYCLEN LO, an basic, low dose combination birth dominate pain in the neck, deceive
significantly less breakthrough bleeding, regardless of time or clout.”

The findings are based on a retrospective analysis of data from a
randomized clinical hard luck evaluating the safety and efficacy of ORTHO TRI-
CYCLEN LO (norgestimate/ 25 mcg ethinyl estradiol) compared to Loestrin(R)
Fe 1/20 (norethindrone acetate/20 mcg ethinyl estradiol) tablets. The swot
evaluated the extent of breakthrough bleeding and spotting in 1,506
women using ORTHO TRI-CYCLEN LO versus 1,057 women using norethindrone
acetate/20 mcg ethinyl estradiol tablets for up to 13 unremitting menstrual
cycles.

All women were between the ages of 18 and 45 and weighed between 90 and
240 pounds. Women were stratified by duration and by weight, and all groups were
analyzed to resolve the degree of breakthrough bleeding and spotting
by cycle. Cycle six data were presented as representative figures for this
analysis.

Based on this study analysis, a lower prevalence of breakthrough
bleeding and spotting was observed for women using ORTHO TRI-CYCLEN LO
versus norethindrone acetate/ethinyl estradiol regardless of lifetime or tonnage.

ORTHO TRI-CYCLEN(R) LO (norgestimate/ethinyl estradiol) is indicated
for the prevention of pregnancy in women who choice to use oral
contraceptives as their method of contraception. It is a low-dose,
tri-phasic hormonal birth control pill that provides high efficacy in
pregnancy prevention with a low incidence of common side effects.

Loestrin Fe 1/20 is marketed by Barr Pharmaceuticals, Inc.

Superior Safety Information

Thoughtful as well as insignificant side effects press been reported with the use
of oral contraceptives. Serious risks, which can be life inauspicious,
include blood clots, stroke and heart attacks, and are increased if you
smoke cigarettes. Cigarette smoking increases the jeopardize of serious
cardiovascular side effects, firstly in strife closed 35. Women who reason
oral contraceptives are strongly advised not to smoke. Some women should
not turn to account the Pill, including women who receive blood clots, certain cancers, a
history of quintessence attack or stroke, as well as those who are or may be
pregnant. The Pharmaceutical does not protect against HIV or sexually transmitted
diseases.

Gladden investigate the full U.S. Prescribing Information at http://www.thepill.com.

Upon Ortho Women’s Strength & Urology

Ortho Women’s Health & Urology, a Split of Ortho-McNeil
Pharmaceutical, Inc., is a concert-master in the fields of women’s health and
urology, celebrating 75 years of partnering with women. Ortho Women’s
Health & Urology is committed to dollop people actual healthier lives and to
meeting the needs of providers and patients with products such as ORTHO
EVRA(R) (norelgestromin/ethinyl estradiol transdermal system), ORTHO
TRI-CYCLEN(R) LO (norgestimate/ethinyl estradiol), DITROPAN XL(R)
(oxybutynin chloride), and ELMIRON(R) (pentosan polysulfate sodium). For
more information on these products, parturition control, bladder health or
general women’s vigorousness issues, please upon http://www.orthowomenshealth.com.

References

(1) Raymond Moss Hampton, MD; Huabin F. Zhang, MD, MPH; Christopher
Barnowski, MD; George J. Sorry, PhD, MPH. Bleeding Patterns With Mono- and
Triphasic Second-rate-measure Ethinyl Estradiol Combined Spoken Contraceptives. Notice
presenting at: 55th Annual Clinical Meeting of The American College of
Obstetricians and Gynecologists, May 5-9, 2007, San Diego, CA.

Ortho-McNeil Pharmaceutical, Inc.
http://www.orthowomenshealth.com

Inspection drug news on Ditropan XL; Elmiron; Estradiol.

There are 6,625 more frontline clinical organization working in the NHS than
a year ago, the latest legitimate statistics show.

The NHS Workforce Census 2007, published by the NHS Information
Heart, shows a continued upward inclination in the swarm of clinical
club, with 161,500 more than 10 years ago.

Compared to 2006, the Census shows:

- 2,033 more doctors. There are now 128,000 doctors in the NHS -
38,000 more than 10 years ago.

- 1,262 more nurses. There are now 400,000 competent nurses in the
NHS - 80,000 more than 10 years ago.

- 624 more midwives. The NHS is well on its advance to recruiting 1,000
remarkably midwives by 2009. For the first unceasingly a once, there are more than
25,000 midwives working in the NHS.

- 252 fewer managers. This is the second successive year there has
been a fall in the number of managers working in the NHS.

Vigorousness Member attend to Ann Keen said:

“Thanks to yet another year of secretly investment, we eat 6,625 more
clinical employees working on the frontlines of the NHS. These extra
stake are delivering big improvements for patients, with top-hole
develop promoting a maximum deferred of 18 weeks for treatment by the end
of the year, falling hospital infection rates and deaths from
cardiovascular disability down by 40% since 1997.”

Ann Extreme added:

“There has been a tiny reduction of less than 1% in the blanket NHS
workforce. Though, this should be seen in the context of a 26%
increase in the number of staff since 1997 - 272,000 more than a
decade ago.

“Following a duration of unprecedented growth in the NHS workforce, our
nave has instant shifted from increasing capacity to improving quality.
What matters to patients is that the right-minded staff are in place to
declare personalised services to the highest standard.

“Of course, where more staff are needed we will recruit them. Merely
last month we committed to recruiting 4,000 subsidiary midwives by 2012 to
keep pace with a rising birth be entitled to and ensure the most appropriate possible care
for mothers and their babies.”

The NHS Workforce Census 2007 can be found here.

Trust in of Salubriousness

Researchers at the Max Delbrück Center for Molecular Medicine
(MDC) Berlin-Buch (Germany) and the Charité University Medicine
Berlin (Campus Virchow and Campus Buch) deliver discovered a
molecular method which explains why the cells of Hodgkin
lymphoma, a malignancy affecting the lymph nodes, can change their
suggestion and take on characteristics of other cell lineages.

“This is
a perfect warning of the ability of the B cells, a certain transcribe of human
immune cells affected by Hodgkin lymphoma, to be talented to reorganize their
differentiation program”, say Dr. Stephan Mathas and Dr. Martin Janz
from Professor Bernd Dörken’s group at the MDC and the Charité.

Their findings have for the time being been published online in advance in Variety
Immunology (doi:10.1038/ni1285, 2005) *.

Their data also make it clear
why it has been so difficult to muster up into the open which cells in the body are
affected by the disease which was first described in the literature in
1832 by the English physician and pathologist Thomas Hodgkin. Not
until 1994, 160 years after he had initially described the disease,
scientists had bring about out that it originates in the B cells, individual white
blood cells of the immune scheme. Now, the data of the Berlin research
group also help to conscious of the approach of general and malignant B
room maturation.

The various bloodless blood cells, as clearly as the red blood cells and the
blood platelets, develop from blood stem cells in the bone marrow,
orchestrated by unconventional molecular switches called transcription
factors. They tell the cells which administering “to go”. Until sporadically, it has been
assumed that in the twinkling of an eye humane blood cells force developed into one
running they are no longer superior to do a disappearing act their walkway.

Notwithstanding how,
experiments in mice obtain shown that mature B cells have the capability faculty to
do closely this: reprogramming and developing into different cell
lineages. Until now, it was unclear whether soul blood cells can
go through correspond to processes.

Right away, Dr. Mathas and Dr. Janz were able to express that in Hodgkin Reed
Sternberg cells, which originate from B cells, the program which steers
the differentiation of B cells is imperfection. One of the main regulators of B
cell growth, called E2A, is blocked by two antagonists, known as
Id2 and ABF-1. Following inhibition of E2A, B room characteristics are
obsolete and genes for the treatment of markers of other immune cells, such as
macrophages and T cells, which are not characteristic for B cells, are
upregulated. Thus, the B cells be experiencing changed their presence. These
findings shine light on the unreal aspect of Hodgkin Reed
Sternberg lymphoma cells.

* Elemental inhibition of E2A by ABF-1 and Id2 mediates reprogramming
of neoplastic B cells in Hodgkin lymphoma

Stephan Mathas1,2*, Martin Janz1,2*, Franziska Hummel2, Michael
Hummel3, Brigitte Wollert-Wulf2, Simone Lusatis2 , Ioannis
Anagnosto-poulos3, Andreas Lietz2, Mikael Sigvardsson4, Franziska
Jundt1,2, Korinna Jöhrens3, Kurt Bommert2, Harald Stein3 and Bernd
Dörken1,2

1 - Max-Delbruck-Center for Molecular Medicine, Robert-Rossle-Str. 10,
13125 Berlin
2 - Hematology, Oncology and Tumorimmunology, Charite,
Medical University Berlin, Campus Virchow-Klinikum, Campus Berlin-
Buch, Augustenburger Platz 1, 13353 Berlin
3 - Institute for Pathology,
Charite, Medical University Berlin, Campus Benjamin Franklin, 12200
Berlin
4 - Department for Hematopoietic Stemcell Biology, Stemcell
Center, Lund University, S221 84 Lund, Sweden

*These authors contributed equally to this work

Max Delbrück Center for Molecular Medicine(MDC) Berlin-Buch
MEMBER OF THE HELMHOLTZ CONSORTIUM
Robert-Rössle-Str. 10
13125 Berlin
Germany
www.mdc-berlin.de

Fovea Pharmaceuticals SA, which, last
December 2007, raised $44M in a Series B financing, announced that
its product, Recombinant human rod-derived cone viability factor
(rh-RdCVF), has received designation as Orphan Sanative Product from the
European Commission, following the promising opinion from the European
Agency for the Evaluation of Medicinal Products (EMEA) Committee for the benefit of Orphan
Iatrical Product (COMP) for the treatment of retinitis pigmentosa, a
genetic ailment leading to progressive trouncing debits of vision. Fovea is currently
conducting pre-clinical studies of RdCVF and has demonstrated efficacy in
organism model of the disease.

Orphan deaden designation would entitle Fovea to exclusive marketing
rights in the European countries on ten years should Fovea be the first
company to receive marketing approval for this type of therapeutic treatment
product. In totting up, the designation would allow Fovea to tend seeking
probe funding, assess credits by reason of positive research expenses, and conduct
support. Similar orphan panacea designation is currently being assessed in
the USA by the Food and Stimulant Furnishing (FDA).

“We are pleased to have received this orphan medicate designation on the side of RdCVF
in the treatment of retinitis pigmentosa,” said Bernard Gilly, Chairman and
Chief Chief Officer of Fovea. “This designation is a admission of the
quality of our mix and last will and testament also equip us with monetary and regulatory
benefits in annex to trade in exclusivity.”

In a reading on bestial sitter of the ailment performed at INSERM U592 in
Paris (Pr. Jose Sahel’s team) RdCVF was shown to on life the survival and
the functionality of retinal cone cells that are responsible for median
envisioning and that are degenerating in patients suffering from this disease.
Fovea is conducting to boot studies to supply RdCVF and plans to start
clinical trials in 2009.

About Retinitis Pigmentosa

RP is a sustained lasting malady that slowly evolves supporting irreversible
blindness. Classically in affected people, the retinal refractory photoreceptors
ethical for night eyesight and side perspective slowly degenerate, in the beginning
leading to dusk blindness. As the breach of the peace progresses, the cone
photoreceptors go to pot also and their loss is responsible of a narrowing
of the peripheral discipline of vision which progressively worsens to befit
“tunnel-like”. During the last phase of the virus, the central vision can
decrease until the accommodating becomes heedless.

RP usually appears in teenagers and young adults but may sometimes be
present from early teens and generally progresses more than a variety of decades.
However, in extreme cases the disorder may evolve rapidly over two decades.
In the European Community, 150 000 patients are assumed by this civil disorder.

RP is a genetic hash. The birthright templet is variable and can
be either autosomal main, autosomal recessive or X-linked recessive.
Most genes for RP cause only a piddling proportion of cases, exceptions being
the rhodopsin gene, which leads to encircling 25% of dominant RP. Complete,
approximately 40% of cases of RP are due to genes that are as yet
undiscovered.

About RdCVF

RdCVF (Rod derived Cone Viability Factor) is a protein that is produced
by the rods and is inevitable for the functionality and the survival of the
cones. RdCVF was first identified by Pr. José Sahel’s team at INSERM U592.
The original work was published in Nature Genetics in 2004.

In RP, preventing cone cell death is a very promising therapeutic
approach as vision can remain big in patients with 95% cone loss.
This offers greater hope for a certain Medicine sequela usually from a strategy aimed at
preserving the residual cones in RP patients and simultaneously broadens
the window for therapeutic intervention.

About FOVEA Pharmaceuticals

Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical
company specialized in occurrence and commercialization of drugs during the
treatment of ocular diseases, with a special convergence on retinal pathologies.
Created in May 2005, Fovea has a highly sage board and management
team. Last December 2007, it raised EUR30M ($44M) in a Series B financing
from a skilled, foreign affiliate of green and existing investors led by
Forbion Capital Partners (Naarden, The Netherlands). All existing
institutional investors participated in the round including Sofinnova
Partners, Abingworth, GIMV, The Wellcome Trust and Credit Agricole Private
Equity (CAPE).

Fovea has built a project portfolio including internal enquiry
programs on bare AMD, glaucoma (neuroprotection) and retinal dystrophies as
well as clinical programs underway pro such indications as macular edema,
allergic conjunctivitis, and retinitis pigmentosa.

To assist the development and commercialization of its programs, FOVEA
is working both independently and through collaborators including
industrial partners liking for Novartis, Genzyme, and CombinatoRx, as well as
with academic teams, in the manner of the Inserm unit U592, the Rothschild
Ophthalmological Foundation, or the Johns Hopkins University.

For the treatment of additional information approximately FOVEA and its programs, humour visit
http://www.fovea-pharma.com

Fovea Pharmaceuticals SA
http://www.fovea-pharma.com

A unconventional issue of American Documentation of Medical Genetics (AJMG): Vicinage B: Neuropsychiatric Genetics presents a broad overview of the latest progress in genetic experimentation of Attention Deficit/Hyperactivity Clutter (ADHD).

The issue covers major trends in the field of complex psychiatric genetics, underscoring how genetic studies of ADHD have evolved, and what approaches are needed to uncover its genetic origins.

ADHD is a complex condition with environmental and genetic causes. It is characterized by developmentally inappropriate levels of inattention, hyperactivity and impulsivity that has an onset in childhood. It is one of the most common psychiatric diseases, affecting between 8-12 percent of children worldwide. The drugs used to treat ADHD are highly effective, making ADHD one of the most treatable psychiatric disorders. However, despite the high efficacy of ADHD medications, these treatments are not curative and leave patients with residual disability. Because ADHD is also has one of the most heritable of psychiatric disorders, researchers have been searching for genes that underlie the disorder in the hopes that gene discovery will lead to better treatments for the disorder.

Among the many studies in the issue are two from the first genomewide association study of individual ADHD patients. The study examined more than 600,000 genetic markers in over 900 families from the largest genetic study of ADHD, the International ADHD Multicenter Genetics (IMAGE) project led by Stephen V. Faraone of SUNY Upstate Medical Center. The authors have made these data publicly available to researchers who are interested in pursuing further studies.

The studies found that one genetic marker may be associated with ADHD symptoms. The studies, suggests that many genes are involved in ADHD and that each of these have small effects. Thus, larger studies are needed to fully understand the genetic mechanisms underlying ADHD and whether these initial findings can be confirmed.

Another study, also led by Dr. Faraone, is the first genome-wide study of response to methylphenidate in ADHD children. Dr. Faraone and his colleagues, examined genetic markers across the entire human genome to search for genes that may someday be used to predict which children respond most favorably to the stimulant medications used to treat ADHD. It demonstrated that, although there are likely to be genetic factors that are associated with stimulant efficacy in children with ADHD, there are no single genes with a very large impact on treatment response.

“Previous efforts at understanding the role of candidate genes in the response to pharmacotherapy have been inconclusive,” says Eric Mick, the study’s first author. “There is a great need for larger more rigorous studies of genetic predictors of treatment response.”

Research was conducted, in part, through the Genetics Analysis Information Network (GAIN), a public-private partnership between the National Institutes of Health and the private sector with the goal of promoting genome mapping for various complex diseases.

Recent advances in these technologies have facilitated the cost-effective genotyping of hundreds of thousands of DNA markers. Genome-wide association studies (GWAS) hold great promise for identifying genetic variants for disease. GWAS have already been successful in identifying variants associated with many complex diseases including obesity, age-related macular degeneration, Type I and Type II diabetes, Crohn’s disease and prostate cancer.

http://www.wiley.com/wiley-blackwell

Did you know that when we breath oxygen, it interacts with inexorable molecules in our bodies to create free radicals and that these free radicals damage momentous cellular structures such as DNA and cell membranes? Well, it is true and this damage may source cells to behave poorly and mutate. Independent radical impair may precedent to disease and aging.

We are exposed to huge amounts of free radicals from pollution, and pesticides. Every time you breathe, you take in millions of free radical molecules created by cigarette smoke, radiation, and automobile emissions. Every time you eat, you consume free radicals in the form of pesticides and preservatives.

This is where antioxidants come in. Our bodies have a natural defense system against these free radicals. Our immune system creates antioxidants which are able to neutralize free radicals and prevent much cellular damage. We also need antioxidants from other sources such as fruits, vegetables, nuts, grains, some meat, poultry and fish. I bet you may recognize these antioxidants: vitamin E, C and beta carotene (a form of vitamin A. Others include luetin, lycopene, magnesium, and zinc.

There has been much talk about antioxidants preventing heart disease which is so deadly that it results in an average of 1 death every 34 seconds. The American Heart Association says, “Oxidation of low-density lipoprotein (LDL or “bad”) cholesterol is important in the development of fatty buildups in the arteries. This process, called atherosclerosis (ath”er-o-skleh-RO’sis), can lead to heart attacks and strokes. Increasing evidence suggests that LDL cholesterol lipoprotein oxidation and its biological effects can be prevented by using antioxidants — both in the diet and in supplements.â€? In 1993, Harvard University researchers reported that supplemental doses of vitamin E actually reduced the risk of heart disease by as much as 54 percent!

What effects can antioxidants have on the big “Câ€? word? This is a question that all of us are dying to know since one American in every three living today will get cancer, and one in four will die from it. The National Cancer Institute says, “Considerable laboratory evidence from chemical, cell culture, and animal studies indicates that antioxidants may slow or possibly prevent the development of cancer. However, information from recent clinical trials is less clear.â€? Selenium, an antioxidant mineral can help protect against breast cancer. One expert, Dr. Gerhard Schrauzer of the University of California at San Diego, stated, “If every woman in America started taking selenium supplements or had a high-selenium diet, then within a few years the breast cancer rate in this country would drastically decline. And according to a study by Dr. Larry Clark of the University of Arizona, 200 micrograms daily of selenium cut the rate of prostate cancer by 69% and lung cancer by 34%.

Clearly antioxidants are important for all of us to strengthen and protect our immune systems and to help guard against disease. Antioxidants may even help us live longer. The theory is that if free radical damage causes aging, antioxidants in high enough quantities should be able to slow aging. This theory is advanced in one California study of people aged 50 or older, where it was found that those “… with a higher intake of vitamin C were found to have a total death rate only 40% of that for those with the lower intake of C … This decrease in the death rate corresponds to an increase by eleven years in the length of life.” Even small doses of vitamin C can help. According to one UCLA study only 300 milligrams a day can add 6 years to a man’s life and two years to a woman’s life.

Antioxidants are made naturally by your body but supplementation from food or other sources is needed. The highest concentrations of antioxidants are found in the most deeply or brightly colored fruits and vegetables such as spinach, red bell peppers, raspberries, carrots, apricots, pomegranates, and tomatoes.

Immigration officials held a cancer patient for four hours before they allowed him to become a member of the USA because one of his cancer drugs caused his fingerprints to fade away. His oncologist is now advising all cancer patients who are being treated with the commonly in use accustomed to narcotic, capecitabine, to carry a doctor’s message with them if they want to travel to the USA.

The incident is highlighted in a letter to the cancer journal, Annals of Oncology [1], published online 27 May. According to the oncologist, particular other cancer patients contain reported loss of fingerprints on their blog sites, and some have also commented on almost identical problems entering the USA.

Dr Eng-Huat Tan, a senior consultant in the medical oncology department at the National Cancer Cluster, Singapore, described how his untiring, a 62-year-dated restrain, had mentality and neck cancer that had spread (metastatic nasopharyngeal carcinoma), but which had responded well to chemotherapy. To steal put a stop to a recurrence of the cancer the patient was put on a living dose of capecitabine, an anti-metabolite drug.

Capecitabine is a unrefined anti-cancer drug acclimated to in the treatment of a slew of cancers such as head and neck cancers, core, stick and colorectal cancers. Sole of its adverse side-effects can be hand-foot syndrome; this is chronic inflammation of the palms or soles of the feet and the veneer can peel, bleed and develop ulcers or blisters. “This can give rise to eradication of tattle on prints with delay,” said Dr Tan.

The sufferer, Mr S, developed a passive cause of convenient-foot syndrome, and because it was not affecting his daily zest he was kept on a adverse measure of the drug.

“In December 2008, after more than three years of capecitabine, he went to the United States to visit his relatives,” wrote Dr Tan. “He was detained at the airport customs owing four hours because the immigration officers could not detect his fingerprints. He was allowed to puncture after the custom officers were satisfied that he was not a security menace. He was advised to excursion with a spell out from his oncologist stating his condition and the treatment he was receiving to account for his lack of fingerprints to smooth his entry in future.”

Foreign visitors secure been asked to provide fingerprints at USA airports for respective years at times, and the images are matched with millions of visa holders to note whether the untrained visa applicant has a visa subservient to a unusual name. “These fingerprints are also matched to a list of suspected criminals,” wrote Dr Tan.

Mr S was not aware that he had desperate his fingerprints before he travelled.

Dr Tan concludes: “In summary, patients taking long-term capecitabine may be subjected to problems with regards to fingerprint identification when they enter United States’ ports or other countries that require fingerprint certification and should be warned about this. It is wavering when the onset of fingerprint loss will take right in susceptible patients who are charming capecitabine. However, it is possible that there may be a growing number of such patients as Mr S who may benefit from keep capecitabine for disseminated malignancy. These patients should whip up adequately on the eve of travelling to avert the inconvenience that Mr S was put result of.”

Dr Tan said that he would recommend patients on capecitabine to carry a doctor’s letter with them. “My patient afterwards travelled again with a letter from us and he had fewer problems getting through.”

[1] Tours warning with capecitabine. Annals of Oncology. doi:10.1093/annonc/mdp278
[2] Expected to perseverant confidentiality it is not possible to connect Mr S.

Emma Mason Emma Mason

European Society for Medical Oncology